Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 10/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163666 | 0.85 | MAPK14 (0.47) | MAPTRHOALMNANPC1RAB9A | |
| SCHEMBL14542584 | 0.83 | RHOA (0.42) | MAPTRHOALMNATP53POLB | |
| SCHEMBL5348339 | 0.81 | MAPT (0.51) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5407681 | 0.75 | MAPT (0.44) | MAPTTP53 | |
| SCHEMBL5165451 | 0.74 | PPARG (0.52) | MAPTLMNATP53NPC1RAB9A | |
| SCHEMBL5162953 | 0.73 | L3MBTL1 (0.50) | MAPTLMNATP53POLBNPC1 | |
| SCHEMBL5165350 | 0.73 | L3MBTL1 (0.50) | MAPTLMNATP53NPC1RAB9A | |
| SCHEMBL14539769 | 0.73 | L3MBTL1 (0.49) | MAPTLMNATP53NPC1RAB9A | |
| SCHEMBL5357341 | 0.72 | TP53 (0.45) | MAPTTP53 | |
| SCHEMBL5349981 | 0.70 | F10 (0.50) | MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199133-B2 | Derivatives of phenoxy-n-′4-(isothiazolindin-1, 1-dioxid-2yl)phenyll-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | MERCK PATENT GESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-7199133-B2 | Derivatives of phenoxy-n-′4-(isothiazolindin-1, 1-dioxid-2yl)phenyll-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | MERCK PATENT GESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20040254175-A1 | Derivatives of phenoxy-n-'4-(isothiazolindin-1,1-dioxid-2yl)phenyl!-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | MERCK PATENT GMBH (DE) | 2004-12-16 | — | — | US | disclosed |
| WO-2003039543-A1 | DERIVATIVES OF PHENOXY-N-'4-(ISOTHIAZOLIDIN-1,1-DIOXID-2YL)PHENY!-VALERIAN- ACID AMIDE AND OTHER COMPOUNDS AS INHIBITORS OF THE COAGULATION FACTOR XA IN THE TREATMENT OF THROMBOEMBOLIC DISEASES AND TUMORS | MERCK PATENT GMBH (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254175-A1 | Derivatives of phenoxy-n-'4-(isothiazolindin-1,1-dioxid-2yl)phenyl!-valerian-acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors | F2, F11, SERPINC1 | MAPT 4492/4885RHOA 2741/4885LMNA 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.